Top

Quality of Life Research

Gepubliceerd in:

01-11-2010

A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients

Auteurs: Regina Rendas-Baum, Min Yang, Francoise Cattelin, Gene V. Wallenstein, John D. Fisk

Gepubliceerd in: Quality of Life Research | Uitgave 9/2010

Abstract

Purpose

The Fatigue Impact Scale (FIS) has been used extensively to assess the impact of fatigue on health-related quality of life (HRQOL) in multiple sclerosis (MS). The objective of this study was to estimate the minimally important difference (MID) of the FIS to facilitate the interpretation of the scale in patients with MS.

Methods

Data came from a cross-sectional study of 184 patients with MS. Anchor-based estimates of the MID were evaluated using patients’ ratings of their own health and a clinical rating of MS severity. Using the proportional odds model, estimates of the MID were evaluated by finding FIS score differences that corresponded to a 50% increase in the odds of poorer health. Convergence between distribution- and anchor-based estimates was assessed.

Results

Nineteen items met the selection criteria for anchors. Triangulation of the anchor- and distribution-based approaches indicated that the MID of the FIS ranged between 10 and 20 points, approximately.

Conclusion

A common metric of meaningful difference of FIS was defined across anchors measuring a broad range of HRQOL domains. The MID estimates in the current study can be used for sample size calculation in the planning of future studies and to aid researchers and clinicians in interpreting FIS score differences in patients with MS.

vorige artikel Validity and reliability of the Bengali version of the Hepatitis Quality of Life Questionnaire

volgende artikel Impact of socioeconomic and clinical factors on child oral health-related quality of life (COHRQoL)

Ream, E., & Richardson, A. (1996). Fatigue: A concept analysis. International Journal of Nursing Studies, 33, 519–529.CrossRefPubMed

Stone, P. C., & Minton, O. (2008). Cancer-related fatigue. European Journal of Cancer, 44, 1097–1104.CrossRefPubMed

Alves, G., Wentzel-Larsen, T., & Larsen, J. P. (2004). Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology, 63, 1908–1911.PubMed

Pittion-Vouyovitch, S., Debouverie, M., Guillemin, F., Vandenberghe, N., Anxionnat, R., & Vespignani, H. (2006). Fatigue in multiple sclerosis is related to disability, depression and quality of life. Journal of the Neurological Sciences, 243, 39–45.CrossRefPubMed

Krupp, L. B., Alvarez, L. A., LaRocca, N. G., & Scheinberg, L. C. (1988). Fatigue in multiple sclerosis. Archives of Neurology, 45, 435–437.PubMed

Janardhan, V., & Bakshi, R. (2002). Quality of life in patients with multiple sclerosis: The impact of fatigue and depression. Journal of the Neurological Sciences, 205, 51–58.CrossRefPubMed

Benito-Leon, J., Morales, J. M., Rivera-Navarro, J., & Mitchell, A. (2003). A review about the impact of multiple sclerosis on health-related quality of life. Disability and Rehabilitation, 25, 1291–1303.CrossRefPubMed

Merkelbach, S., Sittinger, H., & Koenig, J. (2002). Is there a differential impact of fatigue and physical disability on quality of life in multiple sclerosis? Journal of Nervous and Mental Disease, 190, 388–393.CrossRefPubMed

Gruenewald, D. A., Higginson, I. J., Vivat, B., Edmonds, P., & Burman, R. E. (2004). Quality of life measures for the palliative care of people severely affected by multiple sclerosis: A systematic review. Multiple Sclerosis, 10, 690–725.CrossRefPubMed

10.

Whitehead, L. (2009). The measurement of fatigue in chronic illness: A systematic review of unidimensional and multidimensional fatigue measures. Journal of Pain and Symptom Management, 37, 107–128.CrossRefPubMed

11.

Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-based Management Strategies for Fatigue in Multiple Sclerosis. 1998. Washington DC, Paralyzed Veterans of America. Ref Type: Report.

12.

Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77, 371–383.CrossRefPubMed

13.

Cella D., Revicki D., & Sloan J. (2006). Interpreting PRO Results: Methods for Determining Responsiveness and MID. Are patient reported outcomes ready for prime time? The ISOQOL workshop on PROs and the FDA draft guidance for industry. Patient reported outcomes and the global regulatory environment. 10-10-2006. Ref Type: Hearing.

14.

Cella D., Revicki D., & Sloan J. (2006). Interpreting PRO Results: Methods for Determining Responsiveness and MID–presented at ISOQOL 2006. Are patient reported outcomes ready for prime time? The ISOQOL workshop on PROs and the FDA draft guidance for industry. Patient reported outcomes and the global regulatory environment. 10-10-2006. Ref Type: Conference Proceeding.

15.

Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994). Measuring the functional impact of fatigue: Initial validation of the fatigue impact scale. Clinical Infectious Diseases, 18(Suppl 1), S79–S83.PubMed

16.

Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994). The impact of fatigue on patients with multiple sclerosis. Canadian Journal of Neurological Sciences, 21, 9–14.PubMed

17.

Chipchase, S. Y., Lincoln, N. B., & Radford, K. A. (2003). Measuring fatigue in people with multiple sclerosis. Disability and Rehabilitation, 25, 778–784.CrossRefPubMed

18.

Romani, A., Bergamaschi, R., Candeloro, E., Alfonsi, E., Callieco, R., & Cosi, V. (2004). Fatigue in multiple sclerosis: Multidimensional assessment and response to symptomatic treatment. Multiple Sclerosis, 10, 462–468.CrossRefPubMed

19.

Theander, K., Cliffordson, C., Torstensson, O., Jakobsson, P., & Unosson, M. (2007). Fatigue Impact Scale: Its validation in patients with chronic obstructive pulmonary disease. Psychology, Health & Medicine, 12, 470–484.CrossRef

20.

Fisk, J. D., Brown, M. G., Sketris, I. S., Metz, L. M., Murray, T. J., & Stadnyk, K. J. (2005). A comparison of health utility measures for the evaluation of multiple sclerosis treatments. Journal of Neurology, Neurosurgery and Psychiatry, 76, 58–63.CrossRef

21.

Mathiowetz, V. (2003). Test-retest reliability and convergent validity of the Fatigue Impact Scale for persons with multiple sclerosis. American Journal of Occupational Therapy, 57, 389–395.CrossRefPubMed

22.

Ware, J. E., Jr., Snow, K., Kosinski, M., & Gandek, B. (1993). SF-36 Health Survey Manual and Interpretation Guide. The Health Institute. Boston, MA: New England Medical Center.

23.

Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–483.CrossRefPubMed

24.

Pfennings, L., Cohen, L., van der, P. H., Polman, C., & Lankhorst, G. (1998). Reliability of two measures of health-related quality of life in patients with multiple sclerosis. Perceptual and Motor Skills, 87, 111–114.PubMed

25.

Pfennings, L., Cohen, L., Ader, H., Polman, C., Lankhorst, G., Smits, R., et al. (1999). Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life. Journal of Neurology, 246, 587–591.CrossRefPubMed

26.

Mathiowetz, V. G., Matuska, K. M., Finlayson, M. L., Luo, P., & Chen, H. Y. (2007). One-year follow-up to a randomized controlled trial of an energy conservation course for persons with multiple sclerosis. International Journal of Rehabilitative Research, 30, 305–313.CrossRef

27.

Rammohan, K. W., Rosenberg, J. H., Lynn, D. J., Blumenfeld, A. M., Pollak, C. P., & Nagaraja, H. N. (2002). Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: A two centre phase 2 study. Journal of Neurology, Neurosurgery and Psychiatry, 72, 179–183.CrossRef

28.

Rudick, R. A., Miller, D., Hass, S., Hutchinson, M., Calabresi, P. A., Confavreux, C., et al. (2007). Health-related quality of life in multiple sclerosis: Effects of Natalizumab. Annals of Neurology, 62, 335–346.CrossRefPubMed

29.

Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004). Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. British Medical Journal, 329, 253–257.CrossRefPubMed

30.

Ware, J. E., Jr., Kosinski, M., & Keller, S. D. (1994). SF-36 Physical and mental summary scales: A user’s manual. Boston, MA: The Health Institute.

31.

(1990) EuroQol–a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 16, 199–208.

32.

Orme, M., Kerrigan, J., Tyas, D., Russell, N., & Nixon, R. (2007). The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health, 10, 54–60.CrossRefPubMed

33.

Nicholl, C. R., Lincoln, N. B., Francis, V. M., & Stephan, T. F. (2001). Assessing quality of life in people with multiple sclerosis. Disability and Rehabilitation, 23, 597–603.CrossRefPubMed

34.

Parkin, D., Jacoby, A., Mcnamee, P., Miller, P., Thomas, S., & Bates, D. (2000). Treatment of multiple sclerosis with Interferon Beta: An appraisal of cost-effectiveness and quality of life. Journal of Neurology, Neurosurgery and Psychiatry, 68, 144–149.CrossRef

35.

Patten, S. B., Newman, S., Becker, M., Riddell, C., & Metz, L. (2007). Disease management for depression in an MS clinic. International Journal of Psychiatry in Medicine, 37, 459–473.CrossRefPubMed

36.

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology, 33, 1444–1452.PubMed

37.

Noseworthy, J. H. (1994). Clinical scoring methods for multiple sclerosis. Annals of Neurology, 36(Suppl), S80–S85.CrossRefPubMed

38.

Lazek, M. D., Howeison, D. B., & Loring, D. W. (2004). Neurological assessment. Oxford: Oxford University Press.

39.

Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61, 102–109.CrossRefPubMed

40.

Brandt, R. (1990). Assessing the proportionality on the proportional odds model for ordinal logistic regression. Biometrics, 46, 1171–1178.CrossRef

41.

Agresti, A. (2002). Categorical data analysis. Hoboken, New Jersey: John Wiley & Sons.CrossRef

42.

Box, G., & Tidwell, P. (1962). Transformations of the independent variables. Technometrics, 4, 531–550.CrossRef

43.

Tritchler, D. (1995). Interpreting the standardized difference. Biometrics, 51, 351–353.CrossRefPubMed

44.

Cohen, J. A. (1992). A power primer. Psychological Bulletin, 112, 155–159.CrossRefPubMed

45.

McCullagh, P. (1980). Regression models for ordinal data. Journal of the Royal Statistical Society. Series B (Methodological), 42, 109–142.

46.

Steiner, D. L. N. G. R. (1989). Health measurement scales. A practical guide to their development and use. Oxford: Oxford University Press.

47.

Potempa, K. M. (1993). Chronic fatigue. Annual Review of Nursing Research, 11, 57–76.PubMed

48.

Arbizu-Urdiain, T., Martinez-Yelamos, A., & Casado, R. V. (2002). Impairment, disability and handicap scales in multiple sclerosis. Revista De Neurologia, 35, 1081–1093.PubMed

49.

de Groot, V., Beckerman, H., Uitdehaag, B. M. J., De Vet, H. C. W., Lankhorst, G. J., Polman, C. H., et al. (2006). The usefulness of evaluative outcome measures in patients with multiple sclerosis. Brain, 129, 2648–2659.CrossRefPubMed

50.

Hohol, M. J., Orav, E. J., & Weiner, H. L. (1995). Disease steps in multiple sclerosis: A simple approach to evaluate disease progression. Neurology, 45(2), 251–255.PubMed

51.

Midgard, R., Riise, T., & Nyland, H. (1996). Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in More and Romsdal County, Norway. Journal of Neurology, 243(4), 337–344.CrossRefPubMed

52.

Sharrack, B., Hughes, R. A., Soudain, S., & Dunn, G. (1999). The psychometric properties of clinical rating scales used in multiple sclerosis. Brain, 122(Pt 1), 141–159.CrossRefPubMed

53.

Cella, D., Eton, D. T., Lai, J. S., Peterman, A. H., & Merkel, D. E. (2002). Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management, 24, 547–561.CrossRefPubMed

54.

Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., et al. (2004). A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. Journal of Clinical Epidemiology, 57, 898–910.CrossRefPubMed

55.

Hays, R. D., Farivar, S. S., & Liu, H. (2005). Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD, 2, 63–67.CrossRefPubMed

56.

Bjorner, J. B., Wallenstein, G. V., Martin, M. C., Lin, P., Blaisdell-Gross, B., Tak, P. C., et al. (2007). Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Current Medical Research and Opinion, 23, 731–739.CrossRefPubMed

57.

Drulovic, J., Pekmezovic, T., Matejic, B., Mesaros, S., Manigoda, M., Dujmovic, I., et al. (2007). Quality of life in patients with multiple sclerosis in Serbia. Acta Neurologica Scandinavica, 115, 147–152.CrossRefPubMed

58.

Patti, F., Ciancio, M. R., Reggio, E., Lopes, R., Palermo, F., Cacopardo, M., et al. (2002). The impact of outpatient rehabilitation on quality of life in multiple sclerosis. Journal of Neurology, 249, 1027–1033.CrossRefPubMed

59.

Ingles, J. L., Eskes, G. A., & Phillips, S. J. (1999). Fatigue after stroke. Archives of Physical Medicine and Rehabilitation, 80, 173–178.CrossRefPubMed

60.

LaChapelle, D. L., & Finlayson, M. A. (1998). An evaluation of subjective and objective measures of fatigue in patients with brain injury and healthy controls. Brain Injury, 12, 649–659.CrossRefPubMed

61.

Thimineur, M., & De Ridder, D. (2007). C2 area neurostimulation: a surgical treatment for fibromyalgia. Pain Medicine, 8, 639–646.CrossRefPubMed

62.

Benito-Leon, J., Martinez-Martin, P., Frades, B., Martinez-Gines, M. L., de Andres, A. C., Meca-Lallana, J. E., et al. (2007). Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). Multiple Sclerosis, 13, 645–651.CrossRefPubMed

63.

Flensner, G., & Lindencrona, C. (2002). The cooling-suit: case studies of its influence on fatigue among eight individuals with multiple sclerosis. Journal of Advanced Nursing, 37(6), 541–550.CrossRefPubMed

64.

Mathiowetz, V., Matuska, K. M., & Murphy, M. E. (2001). Efficacy of an energy conservation course for persons with multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 82(4), 449–456.CrossRefPubMed

65.

Titel: A novel approach to estimate the minimally important difference for the fatigue impact scale in multiple sclerosis patients
Auteurs: Regina Rendas-Baum
Min Yang
Francoise Cattelin
Gene V. Wallenstein
John D. Fisk
Publicatiedatum: 01-11-2010
Uitgeverij: Springer Netherlands
Gepubliceerd in: Quality of Life Research / Uitgave 9/2010
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-010-9704-7

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 9/2010

Mental health and quality of life survey among child survivors of the 2008 Sichuan earthquake

The relationship between parental overprotection and health-related quality of life in pediatric cancer: the mediating role of perceived child vulnerability

Validity and reliability of the Bengali version of the Hepatitis Quality of Life Questionnaire

Isolated sleep paralysis linked to impaired nocturnal sleep quality and health-related quality of life in Chinese-Taiwanese patients with obstructive sleep apnea

Confirmatory factor analysis of the validity of the SF-12 for persons with and without a history of stroke

Physical activity in different domains and health-related quality of life: a population-based study